DE&I Champions: Maureen Hennessey
Congratulations to Maureen Hennessey for being named to the 2022 PharmaVoice100, as a DE&I Champion! Maureen has been fearless in her dedication and pursuit to address the gaps that exist in today’s healthcare system that lead to medication non-adherence and impact social determinants of health. She continues to inspire all of us by pushing the boundaries on what patient-centric care could and should be for all populations. Check out Maureen’s complete profile in PharmaVoice below: Congratulations to Maureen Hennessey for being named to the 2022 PharmaVoice100, as a DE&I Champion! Maureen has been fearless in her dedication and pursuit to address the gaps that exist in today’s healthcare system that lead to medication non-adherence and impact social determinants of health. She continues to inspire all of us by pushing the boundaries on what patient-centric care could and should be for all populations. Check out Maureen’s complete profile in PharmaVoice here!
Don’t Miss Any of Our Upcoming Precision Value & Health Events. Get the September Events Calendar.
Check out our September Events Calendar, and stay up to date with all of the upcoming and on-demand Precision events and thought leadership! Download Now!
Hear From Key Stakeholders: The Future Treatment and Access Landscape for Cell & Gene Therapies Roundtable
NEW WHITE PAPER!
Earlier this year, Precision Value & Health, in association with Precision ADVANCE, hosted an in-depth, live roundtable: The Future Treatment and Access Landscape for Cell and Gene Therapies— assembling the perspectives of:
- Patient advocates
- National health plans
- Regional health plans
- Medicaid health plans
- Self-funded employer benefit consultancies
- Healthcare systems
- Hematologists/Oncologists
- Neurologists
Dan Vanderpoel, Executive Vice President of PRECISIONvalue, and Dominic Galante, MD, Precision’s Chief Medical Officer, co-moderated the discussion covering a wide range of topics, with the group providing insights, first-hand examples and looks ahead.
And now…you can “listen in” to this exclusive panel of diverse perspectives in our new white paper, summarizing the complete roundtable discussion along with providing key takeaways and future considerations for manufacturers.
Don’t miss out on your chance to grab a free copy of this valuable resource— just click here for yours!
Don’t Miss Any of Our Upcoming Precision Value & Health Events. Get the August Events Calendar.
Don’t miss any of our upcoming Precision Value & Health Events! Download the events calendar and stay up to date with all our thought leadership. Download Now!
MAPS Webinar: The Critical Role of Medical Affairs in Early R&D
In partnership with Precision VH, this webinar is a virtual panel discussion where experts will describe and debate the contributions that Medical Affairs can make to early R&D (preclinical through Ph-IIb).
New PRECISIONheor-led Study Examines Challenges in Capturing Economic Burden of Cancer
Congratulations to Suepattra May-Slater and the PRECISIONheor team for their contributions to a impactful study just published in the journal MMS Policy and Practice. The paper, entitled: “Estimating Productivity Loss from Breast and Non–Small-Cell Lung Cancer among Working-Age Patients and Unpaid Caregivers: A Survey Study Using the Multiplier Method” outlines the challenges in truly capturing the economic burden of cancer for both patients and their caregivers.
Cell & Gene Day is August 24
As a wave of up-and-coming cell and gene therapies eye the path to approval soon, a combination of uncertainties threatens the waters ahead. A lack of talent, shortage of manufacturing, standardization, and shifting infrastructure are just the beginning of a range of potential issues.
Join Endpoints News and Precision ADVANCE for Cell & Gene Day, a free virtual event on August 24, from 12:00-4:00 PM ET where we convene three distinguished panels of experts to find out where the field stands today and explore funding, development and launch strategies to smooth out the ride to commercialization. You will hear from successful innovators from each facet of the CGTx landscape, including executives from Blackstone, Flagship Pioneering, Monograph Capital, Alliance for Regenerative Medicine, Satellite Bio, Cellevolve Bio, and more.
A Novel Data and Analytics-Informed Approach to Launch Excellence
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
Join Precision launch expert veterans for a live webinar discussion of the critical elements of a personalized, integrated and sustainable launch strategy.
- Learn about key challenges to launch success
- Understand how to de-risk and optimize commercial launch planning by better aligning efforts and managing expectations
- Learn how integrating real-world data and innovative analytic models can better inform strategy and execution across stakeholders, for greater impact/effectiveness and efficiency
The discussion will conclude with a live Q&A.
Precision Drug Utilization Management: The Future of Oncology Medication Management
The exponential spending growth in oncology has resulted in myriad utilization management strategies by both payers and providers to control costs, especially drug costs. Precision’s Julianna Kula, Bruce Edelen, Ronald Schleif, Jeffrey Becker, Mark Urban, and Elizabeth Oyekan explore current and emerging drug utilization management strategies being employed to help curtail oncology costs without adversely impacting patient quality and outcomes.
Judge Strikes Down ‘Accumulator Rule,’ Ending Potential Threat to Patient Assistance
More pushback against copay programs likely on the horizon: Precision’s Ryan Cox and Reta Mourad, PharmD, FNTP discuss why a federal court’s decision striking down a CMS rule that would have narrowed the exclusions from Medicaid best price for manufacturer-provided patient-assistance programs, as well as a recent pharma lawsuit against a maximizer company, could spur more states to take action of their own.